Medical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are ...

Dasiglucagon is a glucagon analog formulated in a ready-to-use aqueous solution. It is being reviewed for congenital hyperinsulinism (CHI), a rare genetic disease that affects newborns and children ...

FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S. Phase 3 study for ersodetug for the treatment of tumor HI expected to com ...

Analyst Jason Butler of JMP Securities reiterated a Buy rating on Rezolute (RZLT – Research Report), retaining the price target of $7.00.

FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S.Phase 3 study for ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine ...

Rare disease biotech Rezolute recently announced that the FDA has lifted the partial clinical hold on RZ358 (ersodetug), a ...

The lift is based on new research showing that the previous adverse effects in laboratory rats may not have been caused by ...

The trial will begin enrolling US participants early next year, with topline data expected in the second half of the year.

from being investigated in a Phase III trial for treating hypoglycaemia caused by congenital hyperinsulinism (HI). This regulatory decision will help the company include US participants in the ...

The FDA concluded that the liver toxicity observed was likely specific to a particular type of rats called Sprague Dawley, ...

The drug is aimed at treating low blood sugar caused by congenital hyperinsulinism, a genetic condition in which the insulin cells of the pancreas secrete too much insulin. Those cells normally ...